NCT07537205Enrolling by invitation
The Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Liver Cancer: Study and Protocol
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to to learn if the nurse-led TGA-based Pre-rehabilitation planning can improve compliance, preoperative functional reserve, and reduce the incidence of postoperative complications in patients with hepatocellular carcinoma. The main questions it aims to answer are: 1. Can this pre-rehabilitation program improve patients' perioperative motor function? 2. Can this pre-rehabilitation program enhance patients' perioperative nutritional status? 3. Can this pre-rehabilitation program improve patients' psychological state? 4. Can this pre-rehabilitation program increase patients' overall compliance? Meanwhile, secondary outcome indicators included complication incidence rate, 30-day readmission rate, first anal flatus passage time, hospitalization duration, serum prealbumin, serum albumin, prothrombin time, total bilirubin, satisfaction and quality of Life. Researchers will compare the control group received only ERAS care after the patient's admission to see if the program is effectiveness. Participants who received the intervention group protocol will initiate pre-rehabilitation measures more than 7 days prior to hospital admission, including nutritional support, exercise and respiratory function training, psychological empowerment, pain pre-management, and smoking/alcohol cessation. These interventions will be recorded daily according to the achievement thresholds established by the research team based on outpatient assessment results. After admission, the patients in this group will receive the same EARS care as the control group.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- First submitted
- 6 Apr 2026
- Start date
- 8 Oct 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Fudan University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07537205
What you commit to
- Study type: Interventional
- Planned participants: 92
- From 8 Oct 2025 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (5) Patients who abandon surgical treatment midway.
Other illness
- (1) Patients with severe cognitive impairment or psychiatric disorders.
- (2) Patients with severe cardiorenal or cerebral organ failure.
Other
- (3) Patients who have participated in other research projects.
- (4) Patients requiring reoperation due to severe postoperative complications.
- (6) Patients who voluntarily discontinue the implementation of prehabilitation programs.
Who the study is looking for
- (1) Diagnosis of hepatocellular carcinoma based on the Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition) or the Diagnosis Guidelines for Hepatic Metastases of Colorectal Cancer (2025 Edition).
- (2) Patients undergoing elective liver resection after medical evaluation.
- (3) Patients aged from 18-84 years;.
- (4) Voluntary participation in this study.
Age in the registry: 18 years to 84 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.